Hold on LYTENAVA: FDA Binary and Cash Runway Make This One Too Risky to Buy Now
LYTENAVA sits at a classic biotech crossroads: potential FDA approval that could re-rate the stock versus near-term cash needs that could force dilution. We recommend a Hold. For traders, a tightly risk-managed swing trade is outlined for those who want to play binary upside without being exposed to unlimited downside.